Related Experiment Video
Updated: Jul 9, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Mild cognitive impairment (MCI): a historical perspective
Barry Reisberg1, Steven H Ferris, Alan Kluger
1Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA. barry.reisberg@med.nyu.edu
International Psychogeriatrics
|November 23, 2007
Summary
The Global Deterioration Scale (GDS) stage 3 describes mild cognitive impairment (MCI) as a predementia stage. This stage is distinct from subjective cognitive impairment and mild dementia, with established characteristics and outcomes.
Area of Science:
- Neurology
- Gerontology
- Psychiatry
Background:
- Historical descriptions of dementia date back to antiquity.
- Early diagnostic scales like the Clinical Dementia Rating (CDR) and Global Deterioration Scale (GDS) were developed to identify dementia and its antecedents.
- The GDS stage 3, termed mild cognitive impairment (MCI), represents a predementia condition.
Observation:
- GDS stage 3 MCI is characterized by specific clinical, cognitive, behavioral, and neuroimaging findings.
- It is differentiated from subjective cognitive impairment (GDS stage 2) and mild dementia (GDS stage 4).
- While Petersen's MCI (2001) is widely used, GDS stage 3 MCI includes executive deficits and does not require memory complaints due to potential denial.
Findings:
- GDS stage 3 MCI is a well-characterized predementia stage.
- Longitudinal studies show compatibility in duration and outcomes between GDS stage 3 MCI and Petersen's MCI.
- Key differences include the absence of mandatory memory complaints in GDS stage 3 MCI and its recognition of executive functional deficits.
Implications:
- Understanding GDS stage 3 MCI aids in early identification and potential intervention for cognitive decline.
- The characterization of GDS stage 3 MCI provides a framework for clinical assessment and research.
- Compatibility with Petersen's MCI suggests a consistent understanding of MCI progression and prognosis across different diagnostic criteria.
More Related Videos
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Intellectual Disability
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...